Abstract：Objective To explore the diagnostic value of serum interleukin-6 (IL-6) and carcinoembryonic antigen(CEA) in colorectal cancer and the predictive role of postoperative recurrence. Methods A total of 160 patients with colorectal cancer admitted to the Sixth People′s Hospital of Shanghai Jiaotong University from January 2015 to January 2018 were selected as the colorectal cancer group, a total of 50 patients with benign colon polyps were selected as the benign colon polyp group, and 100 healthy controls during the same period the patient were selected as healthy control group. The serum levels of IL-6 and CEA were observed in the three groups, and the value of serum IL-6 and CEA in the diagnosis of colorectal cancer and the predictive effect of postoperative recurrence were evaluated. Results The positive rate of IL-6 and CEA between the colorectal cancer group Ⅰand the colorectal polyp group was not statistically different (P＞0.05). The positive rates of IL-6 and CEA between the colorectal cancer group Ⅰand the healthy control group in comparison, the difference was not statistically significant (P＞0.05). The positive rates of IL-6 and CEA of stage Ⅱcolorectal cancer were higher than those of colorectal polyp group and healthy control group, the positive rates of IL-6 and CEA of stage Ⅲwere higher than those of colorectal polyp group and healthy control group, and the positive rates of IL-6 and CEA of stage Ⅳwere higher than those of the colorectal polyp group and the healthy control group, and the differences were statistically significant (P＜0.05). IL-6 and CEA predict the AUC of colorectal cancer to be 77.2% and 82.8%. The IL-6 and CEA of the colorectal cancer group after the recurrence group were higher than those of the non-recurrence group, and the differences were statistically significant (P＜0.05). The AUC of IL-6 and CEA for predicting the recurrence of colorectal cancer were 87.3% and 84.1%. Conclusion There are high expressions of IL-6 and CEA in the serum of patients with colorectal cancer. The detection of serum IL-6 is helpful for the diagnosis and prediction of postoperative recurrence in patients with colorectal cancer. It is a supplement to the traditional tumor marker CEA detection.
Ray K，Ujvari B，Ramana V，et al.Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer[J].Cytokine Growth Factor Rev，2018，41（6）：18-27.
[6]
Kallio J，Hamalainen M，Luukkaala T，et al.Resistin and interleukin 6 as predictive factors for recurrence and longterm prognosis in renal cell cancer[J].Urol Oncol，2017，35（5）：525-544.
[7]
Zeng J，Tang ZH，Liu S，et al．Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer[J]．World J Gastroenterol，2017，14（3）：1780-1786.
[9]
Matsuo K，Oka M，Murase K，et al.Expression of interieukin 6 and its receptor in human gastric and coiorectai cancer[J].J Int Med Res，2003，31（2）：69-75.
[10]
Chung SS，Wu Y，Okobi Q，et al.Proinflammatory Cytokines IL-6 and TNF-alpha Increased Telomerase Activity through NF-kappaB/STAT1/STAT3 Activation，and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells[J].Mediators Inflamm，2019，20（7）：59-64.
[11]
Toyoshima Y，Kitamura H，et al.IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells[J]．Cancer Immunol Res，2019，7（12）：1944-1957.
[17]
Wei N，Li J，Fang C，et al.Targeting colon cancer with the novel STAT3 inhibitor bruceantinol[J].Oncogene. 2019，38（10）：1676-1687.
[18]
Lin Y，He Z，Ye J，et al.Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer[J].Onco Targets Ther，2020，21（12）：13023-13032.
京公网安备 11010502046607号